Market Newsdesk

April 6, 2021 2:03 am

Ahold Delhaize share buyback update

Zaandam, the Netherlands, April 6, 2021 – Ahold Delhaize has repurchased 202,407 of Ahold Delhaize common shares in the period from March 29, 2021 up to and including April 1, 2021. The shares were repurchased at an average price of € 23.83 per share for a total consideration of € 4.8 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020.

The total number of shares repurchased under this program to date is 13,655,177 common shares for a total consideration of € 315.4 million.

Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/

This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.

April 6, 2021 2:03 am

Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®

Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3^®

Study Stresses the Importance of Brain Monitoring During the Treatment of Patients with Severe COVID-19

NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Critical Care in which researchers in Genoa, Italy, evaluated the impact of a variety of rescue therapies on the systemic and cerebral oxygenation of mechanically ventilated COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).¹ To gauge the impact, the researchers used the Masimo Root^® Patient Monitoring and Connectivity Platform with O3^® Regional Oximetry, which uses near-infrared spectroscopy (NIRS) to enable monitoring of tissue oxygen saturation (rSO₂) in the region of interest, such as the brain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005487/en/

Masimo Root® with O3® Regional Oximetry and SedLine® Brain Function Monitoring (Photo: Business Wire)

Dr. Chiara Robba and colleagues noted that “neurological complications are common in mechanically ventilated critically ill patients with COVID-19 and may lead to impaired cerebral hemodynamics,” and further, that respiratory rescue therapies “may have detrimental effects on brain physiology.” Observing, however, that there is currently little data available regarding the effect of rescue therapies on these patients’ brains, and in particular on cerebral oxygenation, the researchers sought to assess the impact of different ventilatory rescue therapies on the brain to help guide clinicians in choosing the most appropriate therapies for their COVID-19 patients.

The rescue therapies studied were recruitment maneuvers (RMs), prone positioning (PP), inhaled nitric oxide (iNO), and extracorporeal carbon dioxide removal (ECCO₂R). To assess impact, the researchers measured (before and after the application of each method) arterial oxygen saturation (SpO₂), partial pressure of oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂), and cerebral oxygen saturation (rSO₂). rSO₂ was obtained using Masimo Root with O3, which also allowed them to observe several additional parameters unique to Masimo O3: ΔO₂Hb, which monitors relative changes in the oxygenated hemoglobin component of rSO₂; ΔHHb, which monitors relative changes in the deoxygenated hemoglobin component of rSO₂; and ΔcHb, which monitors relative changes in total cerebral hemoglobin or blood volume. As a secondary aim, the researchers sought to evaluate the correlation between systemic and cerebral oxygenation.

The researchers found that the four rescue therapies had varied impact on cerebral oxygenation and the other measured parameters, noting in particular that after RMs, while there was no significant change in PaO₂ or PaCO₂, there was a significant decrease in rSO₂. After PP and after iNO therapies, both PaO₂ and rSO₂ increased; ΔcHb also increased, corresponding to increased cerebral blood volume. After ECCO₂R, both PaO₂ and rSO₂ decreased.

The researchers concluded, “Rescue therapies exert specific pathophysiological mechanisms, resulting in different effects on systemic and cerebral oxygenation in critically ill COVID-19 patients with ARDS. … The choice of rescue strategy to be adopted should take into account both lung and brain needs.”

They also noted, “To our knowledge, this is the first study investigating the early effects of rescue therapies on systemic and cerebral oxygenation and their correlation in critically ill patients with COVID-19-associated ARDS. The use of multimodal neuromonitoring, including new indices such as ΔHHbi + ΔO₂Hbi, enabled us to better investigate the specific consequences of each ventilatory rescue strategy for brain and lung function. This is particularly important, especially in the early phases after rescue therapies application, when most of the effects on cerebral physiology are mainly acting.”

Dr. Robba and study co-author Dr. Basil Matta, Senior Medical Director at Masimo, commented, “The ability to observe relative changes in oxygenated, deoxygenated, and total hemoglobin with O3’s delta indices provided us with better insight into why brain saturations change as a result of interventions, and allowed us to better understand the interactions between systemic and cerebral hemodynamics. For example, we saw that turning patients prone resulted in improved systemic and cerebral oxygenation, whereas the lung recruitment maneuver did not improve systemic oxygenation, and even had an adverse effect by reducing brain oxygen saturation.”

They continued, “Above all, the main objective of improving the oxygen content of the blood is to deliver oxygen to vital organs, the most important of which is the brain. Masimo O3 provides the clinician with the ability to assess the impact of any medical intervention aimed at improving oxygenation. O3’s hemoglobin indices were critical to our understanding of the effects of our interventions on the brain. Without such a monitor, we are at best guessing, and in danger of flying blind. As we continue to seek to improve care and outcomes for patients with severe COVID-19, any tool that helps us better understand the impact of different medical interventions is most welcome.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.² Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,³ improve CCHD screening in newborns,⁴and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.^5-8Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,⁹ and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.¹⁰ Masimo continues to refine SET^® and in 2018, announced that SpO₂ accuracy on RD SET^® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO₂ values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris^® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

Robba C, Ball L, Battaglini D, Cardim D, Moncalvo E, Brunetti I, Bassetti M, Giacobbe D, Vena A, Patroniti N, Rocco P, Matta B, Pelosi P. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit Care (2021)25:111. DOI: https://doi.org/10.1186/s13054-021-03537-1.
Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
Estimate: Masimo data on file.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Root^® with O3^®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Root with O3, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005487/en/

Masimo

Evan Lamb

949-396-3376

[email protected]

KEYWORDS: Europe Switzerland United States North America California

INDUSTRY KEYWORDS: Medical Devices Infectious Diseases Hospitals Health Medical Supplies

MEDIA:

Logo

Photo

Masimo Root® with O3® Regional Oximetry and SedLine® Brain Function Monitoring (Photo: Business Wire)

April 6, 2021 2:03 am

Caledonia Mining Corporation Plc: Caledonia’s ‘Central Shaft’ Brought into Operation

ST HELIER, Jersey, April 06, 2021 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”)(NYSE AMERICAN: CMCL; AIM: CMCL) is pleased to announce that its Central Shaft is now fully operational.

Commenting on the announcement, Steve Curtis, Chief Executive Officer, said:

“I am delighted to announce that our new Central Shaft, which is the deepest shaft of any gold mine in Zimbabwe, is fully operational. We can now start to hoist rock, men and material on a daily basis, which will solve our hoisting constraints and facilitate the planned expansion in mine capacity targeting 80,000 oz of gold production per year
¹
.

“Commissioning the Central Shaft has been the culmination of a six-year project costing approximately $67million, all funded through internal cash flow.

“This has been an owner-funded and built project by the Blanket team and I would like to thank everyone for their hard work and especially for achieving the completion of the shaft without any serious accidents, recording only two lost time injuries.”

For further information please contact:

Caledonia Mining Corporation Plc Mark Learmonth Camilla Horsfall	Tel: +44 1534 679 802 Tel: +44 7817 841793

WH Ireland Adrian Hadden/James Sinclair-Ford	Tel: +44 20 7220 1751

Blytheweigh Tim Blythe/Megan Ray	Tel: +44 207 138 3204

3PPB Patrick Chidley Paul Durham	Tel: +1 917 991 7701 Tel: +1 203 940 2538

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation (EU) No. 596/2014.

Cautionary Note Concerning Forward-Looking Information

Information and statements contained in this news release that are not historical facts are “forward-looking information” within the meaning of applicable securities legislation that involve risks and uncertainties relating, but not limited, to Caledonia’s current expectations, intentions, plans, and beliefs. Forward-looking information can often be identified by forward-looking words such as “anticipate”, “believe”, “expect”, “goal”, “plan”, “target”, “intend”, “estimate”, “could”, “should”, “may” and “will” or the negative of these terms or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Examples of forward-looking information in this news release include: production guidance, estimates of future/targeted production rates, and our plans and timing regarding further exploration and drilling and development. This forward-looking information is based, in part, on assumptions and factors that may change or prove to be incorrect, thus causing actual results, performance or achievements to be materially different from those expressed or implied by forward-looking information. Such factors and assumptions include, but are not limited to: failure to establish estimated resources and reserves, the grade and recovery of ore which is mined varying from estimates, success of future exploration and drilling programs, reliability of drilling, sampling and assay data, assumptions regarding the representativeness of mineralization being inaccurate, success of planned metallurgical test-work, capital and operating costs varying significantly from estimates, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and other factors.

Security holders, potential security holders and other prospective investors should be aware that these statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Such factors include, but are not limited to: risks relating to estimates of mineral reserves and mineral resources proving to be inaccurate, fluctuations in gold price, risks and hazards associated with the business of mineral exploration, development and mining, risks relating to the credit worthiness or financial condition of suppliers, refiners and other parties with whom the Company does business; inadequate insurance, or inability to obtain insurance, to cover these risks and hazards, employee relations; relationships with and claims by local communities and indigenous populations; political risk; risks related to natural disasters, terrorism, civil unrest, public health concerns (including health epidemics or outbreaks of communicable diseases such as the coronavirus (COVID-19)); availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development, including the risks of obtaining or maintaining necessary licenses and permits, diminishing quantities or grades of mineral reserves as mining occurs; global financial condition, the actual results of current exploration activities, changes to conclusions of economic evaluations, and changes in project parameters to deal with unanticipated economic or other factors, risks of increased capital and operating costs, environmental, safety or regulatory risks, expropriation, the Company’s title to properties including ownership thereof, increased competition in the mining industry for properties, equipment, qualified personnel and their costs, risks relating to the uncertainty of timing of events including targeted production rate increase and currency fluctuations. Security holders, potential security holders and other prospective investors are cautioned not to place undue reliance on forward-looking information. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and various future events will not occur. Caledonia undertakes no obligation to update publicly or otherwise revise any forward-looking information whether as a result of new information, future events or other such factors which affect this information, except as required by law.

This news release is not an offer of the shares of Caledonia for sale in the United States or elsewhere. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the shares of Caledonia, in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such province, state or jurisdiction.

______________________

_{¹

Mr

Dana Roets (B

Eng

(Min.), MBA,

Pr.Eng

., FSAIMM, AMMSA), Chief Operating Officer, is the Company’s qualified person as defined by Canada’s National Instrument 43-101 and has approved any scientific or technical information contained in this news release.}

April 6, 2021 2:03 am

Caledonia Mining Corporation Plc: Caledonia declares another increased quarterly dividend

Highlights

Nine per cent increase from the previous quarterly dividend of 11 cents that was paid in January 2021
75 per cent cumulative increase from the level of 6.875 cents since October 2019
Fifth increase in the quarterly dividend since October 2019
Central Shaft brought into operation during the first quarter of 2021
Target production of 61,000 to 67,000 ounces of gold in 2021 and 80,000 ounces of gold per annum from 2022¹
Scheduled ramp up in production, a firm gold price and good cost control give the Board confidence that the business can sustain a higher level of dividend

Commenting on the announcement, Steve Curtis, Chief Executive Officer, said:

“We are pleased to announce an additional nine per cent increase in our quarterly dividend, the fifth increase in the past 18 months. This represents a cumulative 75 per cent rise in the dividend since the first increase in October 2019. The decision by the Board to increase the dividend reflects our continued confidence in the outlook for our business.

“As we reach the end of the six-year investment programme at Blanket Mine, the anticipated combination of rising production and declining capital investment gives us confidence to further increase the dividend payment in addition to providing funding for investment in new projects, including the exploration prospects at Glen Hume and Connemara North, as announced at the end of 2020.”

The relevant dates relating to the dividend are as follows:

Ex-dividend date: April 15, 2021
Record date: April 16, 2021
Payment date: April 30, 2021

Shareholders with a registered address in the UK will be paid in Sterling.

Caledonia’s Dividend Policy

Caledonia’s strategy to maximise shareholder value includes a quarterly dividend policy which the Board adopted in 2014. The Board will consider future increases in the dividend as appropriate in line with its prudent approach to risk management.

For further information please contact:

Caledonia Mining Corporation Plc Mark Learmonth Camilla Horsfall	Tel: +44 1534 679 802 Tel: +44 7817 841793

WH Ireland Adrian Hadden/James Sinclair-Ford	Tel: +44 20 7220 1751

Blytheweigh Tim Blythe/Megan Ray	Tel: +44 207 138 3204

3PPB Patrick Chidley Paul Durham	Tel: +1 917 991 7701 Tel: +1 203 940 2538

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation (EU) No. 596/2014.

________________________

_{¹

Mr

Dana Roets (B

Eng

(Min.), MBA,

Pr.Eng

., FSAIMM, AMMSA), Chief Operating Officer, is the Company’s qualified person as defined by Canada’s National Instrument 43-101 and has approved any scientific or technical information contained in this news release.}

April 6, 2021 2:03 am

Global Care Capital Announces LOI for Acquisition of CCM Technologies Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — Global Care Capital Inc. (CSE:HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that it has entered into a letter of intent dated April 5^th, 2021 (the “LOI”), which sets out the basic terms and conditions for the acquisition by the Company of all of the issued and outstanding securities in the capital of CCM Technologies Inc. (Cryptocurrency Mining Technologies) (“CCM”), a cryptocurrency mining company with state of the art ASIC chips, in exchange for securities in Global Care (the “Transaction”).

The Company and CCM have entered into the LOI, which sets out certain terms and conditions pursuant to which the proposed Transaction will be completed. The terms outlined in the LOI are subject to the parties successfully entering into a definitive agreement (the “Definitive Agreement”) in respect of the Transaction on or before April 30^th, 2021 or such other date as the Company and CCM may mutually agree. The material terms of the Transaction are as follows:

In consideration for the Transaction, Global Care will issue an aggregate of 95,000,000 common shares of Global Care (the “Consideration Shares”) to CCM shareholders at a deemed price of $0.11 per Consideration Share and issue to CCM warrant holders an aggregate of 65,000,000 common share purchase warrants (the “Consideration Warrants”)
Each Consideration Warrant permits the holder thereof to acquire one Global Care common share at a price of $0.05 until 1 year after the closing of the transaction.
There is no hold period for the Consideration Shares or Consideration Warrants pursuant to applicable securities laws.

The Transaction is an arms-length transaction and no change in management, or the Board of Directors of Global Care is being contemplated at this time. The LOI also contemplates other material conditions precedent to the closing of the Transaction, including the completion of due diligence, compliance with all applicable regulatory requirements and receipt of all necessary regulatory, corporate, third-party, board and shareholder approvals being obtained, including the approval of the Canadian Securities Exchange. There can be no assurance that the Transaction will be completed as proposed, or at all.

“With the proposed acquisition of CCM Technologies, Global Care will expand its portfolio to include ASIC machines as CCM works toward implementing its first phase of a planned datacenter program. The machines can be used to test out proprietary mining software, improve hashrate and expand on existing analytics software. The team at CCM Technologies have proven they have a deep understanding of the industry,” said Alex Somjen, CEO of Global Care Capital.

The goal of the acquisition is to give Global Care shareholders further exposure to cryptocurrency mining infrastructure, which is the backbone and cornerstone of blockchain technology.

CCM Technologies Chief Executive Officer, Lawrence Cofield stated, “We are excited to work with Global Care at this important time in the crypto currency mining sector and create synergies by pairing our pipeline of opportunities and partnerships with leading hardware producers with Global Care’s existing exposure to crypto currency royalty streaming. There is potential to unlock value in numerous digital assets classes through innovative Decentralized Finance strategies (DeFi) with emerging blockchain technologies.”

About CCM Technologies Inc.

CCM Technologies Inc. is a digital asset technology company with a focus on providing infrastructure for the blockchain ecosystem and mining of cryptocurrencies.

Website: https://ccm-technologies.com

About Global Care

Global Care Capital is a global investment company which specializes in providing early-stage financing to private and public companies. The Company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining positions in early-stage investment opportunities that adequately reflect the risk profile.

Website: https://globalcarecapital.com/

GLOBAL CARE CAPITAL INC.:

Company Contact:

Alex Somjen, President & CEO

604-687-2038

[email protected]

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Cautionary Note

All information contained in this news release with respect to CCM was supplied by CCM for inclusion herein, and Global Care’s directors and officers have relied on CCM for such information.

Forward-Looking Information

: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on

www.sedar.com

April 6, 2021 1:58 am

Pomerantz Law Firm Announces the Filing of a Class Action against AgEagle Aerial Systems, Inc. and Certain Officers – UAVS

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against AgEagle Aerial Systems, Inc. (“AgEagle” or the “Company”) (NYSE: UAVS) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-01991, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired publicly traded AgEagle securities between September 3, 2019 and February 18, 2021, inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased AgEagle securities during the Class Period, you have until April 27, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

AgEagle purports to be a commercial drone company. According to AgEagle’s website, the Company is engaged in the design, engineering, and manufacturing of commercial drones, as well as in providing drone services and solutions to the agriculture industry.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) AgEagle did not have a partnership with Amazon and in fact never had any relationship with Amazon; (2) rather than correct the public’s understanding about a partnership with Amazon, Defendants were actively contributing to the rumor that AgEagle had a partnership with Amazon; and (3) as a result, Defendants’ statements about AgEagle’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On October 14, 2020, news broke that Amazon did not have a partnership agreement with AgEagle, and in fact never did. The Wichita Business Journal published a story with the headline: “Exclusive: Who’s AgEagle’s big customer? We now know who it’s not.” The article reported that AgEagle was not partnering with Amazon.

On February 18, 2021, Bonitas Research published a report revealing that AgEagle “was a pump & dump scheme orchestrated by . . . AgEagle founder and former chairman Bret Chilcott and other UAVS insiders to defraud US investors.”

On this news, shares of AgEagle, fell $5.13, or 36.4%, to close at $8.96 on February 18, 2021, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-ageagle-aerial-systems-inc–and-certain-officers–uavs-301262555.html

SOURCE Pomerantz LLP

April 6, 2021 1:57 am

BE Semiconductor Industries N.V. Announces Trading Update

Q1-21 Orders of € 327 Million, Up 108% versus Q4-20 and 176% vs. Q1-20

DUIVEN, the Netherlands, April 06, 2021 (GLOBE NEWSWIRE) — BE Semiconductor Industries N.V. (“the Company” or “Besi”), (Euronext Amsterdam: BESI; OTC: BESIY, Nasdaq International Designation), a leading manufacturer of assembly equipment for the semiconductor industry, today provided a trading update for the first quarter ended March 31, 2021.

Orders for Q1-21 reached a record of € 327 million, an increase of € 170 million, or 108%, versus the € 157.3 million recorded in Q4-20 and an increase of € 208 million, or 176%, versus Q1-20. For the six-month period ending March 31, 2021, orders aggregated € 484 million, an increase of 121% versus the comparable six-month period comprising Q4-19 and Q1-20.

Order strength in Q1-21 reflected a surge in demand across all Besi’s product groups and end user markets. There was particular strength in demand for high end smart phone applications associated with new product introductions offering 5G enhanced features and functionality. In addition, there was significant order growth for automotive applications versus Q4-20 and increased demand for high end logic devices used in high performance computing applications such as AI and data centers. Bookings during the quarter also included initial orders for Besi’s hybrid bonding systems from industry leading customers.

Revenue and operating profit for Q1-21 are anticipated to be within prior guidance for the quarter in terms of revenue, gross margin and operating profit. Besi will report its full results for the first quarter ended March 31, 2021 on April 30, 2021.

About Besi

Besi is a leading supplier of semiconductor assembly equipment for the global semiconductor and electronics industries offering high levels of accuracy, productivity and reliability at a low cost of ownership. The Company develops leading edge assembly processes and equipment for leadframe, substrate and wafer level packaging applications in a wide range of end-user markets including electronics, mobile internet, cloud server, computing, automotive, industrial, LED and solar energy. Customers are primarily leading semiconductor manufacturers, assembly subcontractors and electronics and industrial companies. Besi’s ordinary shares are listed on Euronext Amsterdam (symbol: BESI). Its Level 1 ADRs are listed on the OTC markets (symbol: BESIY Nasdaq International Designation) and its headquarters are located in Duiven, the Netherlands. For more information, please visit our website at www.besi.com.

Contacts:

Richard W. Blickman, President & CEO
Hetwig van Kerkhof, SVP Finance
Tel. (31) 26 319 4500
[email protected]

CFF Communications
Frank Jansen
Tel. (31) 20 575 4024
[email protected]

Caution Concerning Forward Looking Statements

This press release contains statements about management’s future expectations, plans and prospects of our business that constitute forward-looking statements, which are found in various places throughout the press release, including, but not limited to, statements relating to expectations of orders, net sales, product shipments, expenses, timing of purchases of assembly equipment by customers, gross margins, operating results and capital expenditures. The use of words such as “anticipate”, “estimate”, “expect”, “can”, “intend”, “believes”, “may”, “plan”, “predict”, “project”, “forecast”, “will”, “would”, and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. The financial guidance set forth under the heading “Outlook” contains such forward looking statements. While these forward looking statements represent our judgments and expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from those contained in forward looking statements, including any inability to maintain continued demand for our products; failure of anticipated orders to materialize or postponement or cancellation of orders, generally without charges; the volatility in the demand for semiconductors and our products and services; the extent and duration of the COVID-19 pandemic and measures taken to contain the outbreak, and the associated adverse impacts on the global economy, financial markets, and our operations as well as those of our customers and suppliers; failure to develop new and enhanced products and introduce them at competitive price levels; failure to adequately decrease costs and expenses as revenues decline; loss of significant customers, including through industry consolidation or the emergence of industry alliances; lengthening of the sales cycle; acts of terrorism and violence; disruption or failure of our information technology systems; inability to forecast demand and inventory levels for our products; the integrity of product pricing and protection of our intellectual property in foreign jurisdictions; risks, such as changes in trade regulations, currency fluctuations, political instability and war, associated with substantial foreign customers, suppliers and foreign manufacturing operations, particularly to the extent occurring in the Asia Pacific region; potential instability in foreign capital markets; the risk of failure to successfully manage our diverse operations; any inability to attract and retain skilled personnel, including as a result of restrictions on immigration, travel or the availability of visas for skilled technology workers as a result of the COVID-19 pandemic; those additional risk factors set forth in Besi’s annual report for the year ended December 31, 2020 and other key factors that could adversely affect our businesses and financial performance contained in our filings and reports, including our statutory consolidated statements. We expressly disclaim any obligation to update or alter our forward-looking statements whether as a result of new information, future events or otherwise.

April 6, 2021 1:53 am

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FuboTV, Inc. of Class Action Lawsuit and Upcoming Deadline – FUBO

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against FuboTV, Inc. (“Fubo” or the “Company”) (NYSE: FUBO) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-01641, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired common shares of Fubo stock between March 23, 2020 and January 4, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violation of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased FuboTV securities during the Class Period, you have until April 19, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Fubo is a multichannel video programming distributor (“vMVPD”), offering subscribers access to thousands of live sporting events as well as news and entertainment content. Fubo’s platform allows customers to access content through streaming devices, and on SmartTVs, mobile phones, tablets and computers. It streams its services to United States, Canada and Spain. In its regulatory filings and public statements, Fubo positions itself as a content distributor at the intersection of three “megatrends”: cord-cutting, connected TV advertising, and online sports wagering. Fubo revenues are almost entirely derived from the sale of subscription services and advertising in the United States.

Throughout the Class Period, Defendants disseminated false and misleading statements that misrepresented Fubo’s financial health and its operating condition. These misleading statements included representations relating to a variety of Fubo’s business operations and performance metrics, including, among others, Fubo’s ability to grow subscription levels and future profitability, seasonality factors, cost escalations and potentially shrinking addressable market, ability to attract and generate advertising revenue, the Company’s valuation, and its prospects of entering the arena of online sports wagering. For example, one of the Company’s unrealistic promises included courageous claims of the Company’s plans to scale its sport wagering business by, among other things, acquiring Balto Sports, which significantly inflated the price of Fubo securities, and also created a false basis for its valuation and revenue projections. In reality, the Company’s prospects of scaling the sports wagering business was far from realistic given its size and market share, a fact that investors were never apprised of. As some analysts later described Fubo’s strategy, it amounted to “putting a lipstick on a pig.”

Investors learned the truth gradually through a series of research reports beginning on December 23, 2020. Those reports revealed, among others things, that (i) Fubo’s growth in subscriber and profitability was unsustainable past the one-time seasonal surge; (ii) Fubo’s offering of products would be subject to cost escalation; (iii) Fubo could not successfully compete and perform as sports book operator and could not capitalize on its online sports wagering opportunity; (iv) Fubo’s data and inventory was not differentiated to allow Fubo to achieve its long-term advertising growth goals; (v) Fubo’s valuation was overstated in light of its total revenue and subscription levels; and (vi) the acquisition of Balto Sports did not provide the stated synergies and internal expertise, and did not expand the Company’s addressable market into sports wagering.

Upon the publication of the research reports, the price of Fubo securities declined 54% from a close of $52.59 on December 23, 2020 to a close of $24.24 on January 4, 2021.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-fubotv-inc-of-class-action-lawsuit-and-upcoming-deadline–fubo-301262549.html

SOURCE Pomerantz LLP

April 6, 2021 1:52 am

AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19

PRESS RELEASE

AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS

Paris, April 6 2021, 8am CET

AB Science SA (Euronext – FR0010557264 – AB), together with the University of Chicago, today announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans infected with nidoviruses, coronaviruses and picornaviruses.

This collaboration follows the discovery by the University of Chicago that masitinib inhibits the main protease (3CLpro) necessary for the SARS-CoV-2 viral replication cycle [1].

Under this agreement, AB Science will supply masitinib and more than 130 other AB Science proprietary drugs that have demonstrated activity against SARS-CoV-2 main protease 3CL-Pro via virtual screening methodology, and will benefit from the proprietary research platform of the University of Chicago.

The University of Chicago will perform the following research activities:

Enhance the preclinical program of masitinib against SARS-CoV-2
Initiate investigation with masitinib against other viruses that are dependent on protease 3CL-Pro for replication
Test and identify analogues of masitinib active against SARS-CoV-2 protease 3CL-Pro

To secure and consolidate patent positions, AB Science and the University of Chicago will merge their patent rights related to masitinib or masitinib analogues related to virology applications. The University of Chicago’s Polsky Center for Entrepreneurship and Innovation worked with the researchers to file the associated patents and then completed the license agreement with AB Science.

In case of commercialization in viral disease, AB Science will benefit from an exclusive, royalty-bearing license on any discoveries made with AB Science products (1% of net sales on first registered product and 0.3% of net sales on further registered product to be paid to the University of Chicago).

Dr Nir Drayman, researcher at the Pritzker School for Molecular Engineering (University of Chicago) said, “We are delighted to work with AB Science on this global program. The discovery of masitinib as an anti-protease against multiple coronaviruses is a major discovery. Masitinib should be a priority drug to develop against COVID-19 and future emerging viruses. Unfortunately, this pandemic is not over and the world urgently needs anti-virals to combat this virus, and masitinib is a very promising candidate”.

Professor Savas Tay, principal investigator of the 3CLpro inhibitor study and author of the article (Pritzker School for Molecular Engineering, University of Chicago) said. “In a context where we face the emergence of a number of SARS-CoV-2 variants of concern, the development of efficacious anti-viral therapeutics is urgently needed. Because masitinib specifically targets the catalytic residues of 3CLpro, its anti-viral activity is likely to be insensitive to genetic alterations of the Spike protein. Thus, masitinib constitutes a uniquely valuable therapeutic option for both ancestral SARS-CoV-2 and variants against which vaccines or monoclonal antibodies may become less or not effective. This is why we are extremely pleased to collaborate with AB Science and eager to continue our research with masitinib and analogues of masitinib”.

“Collaboration is necessary for the rapid development of new drugs in the fight against this pandemic. We are proud to collaborate in all aspects with the School for Molecular Engineering of the University of Chicago, one of the best research centers in the world. Our ultimate objective in Covid19 is to deliver as soon as possible a drug that is a direct antiviral against the protease of the virus” said Alain Moussy, cofounder and CEO of AB Science.

Professor Olivier Hermine, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France said, “Masitinib could represent an important therapeutic option against SARS-CoV-2 because of its dual mechanism of action. First, masitinib targets the protease, which is a validated scientific strategy to inhibit virus replication, the efficacy of which is not dependent on the emergence of new variants whose mutations primarily affect the virus spike protein but not the protease catalytic site, and second, masitinib bears anti-inflammatory properties that could reduce the cytokine storm”.

Masitinib in COVID-19

Research led by the University of Chicago [1] have shown that masitinib inhibits 3CLpro, a SARS-CoV-2 protease that is crucial for virus infection and reproduction, by directly binding to the protease catalytic site.

Key points from this research article include:
- The study objective was to identify safe-in-human drugs with potential anti-coronavirus properties from an initial library of 1,900 compounds, either approved for human use or with extensive safety data in humans (Phase 2 or 3 clinical trials).
- Masitinib significantly inhibited SARS-CoV-2 replication in human lung cells.
- Notably, masitinib completely inhibited 3CLpro activity. 3CLpro is the SARS-CoV-2 main protease, necessary for its viral replication cycle.
- X-ray crystallography revealed that masitinib directly binds to the active site of 3CLpro, thereby having a direct antiviral activity by blocking its enzymatic activity.
- Masitinib was also effective in blocking the replication of multiple picornaviruses (human pathogens that cause a range of diseases including meningitis, hepatitis, and poliomyelitis).
- Overall, masitinib was shown to have broad anti-coronavirus and anti-picornavirus activity.

A Phase 2 study is on-going to evaluate masitinib in combination with isoquercetin for the treatment of COVID-19. This study (AB20001) is a randomized (1:1), double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The study will enroll 200 patients (age ≥18 without an upper age limit) at medical centers in France and other countries. The primary objective is to improve the clinical status of patients after 15 days of treatment.

[1] Drayman N, Jones KA, Azizi S-A, et al. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro. bioRxiv 2020.08.31.274639; doi: https://doi.org/10.1101/2020.08.31.274639

About the Polsky Center for Entrepreneurship and Innovation at the University of Chicago

The Polsky Center for Entrepreneurship and Innovation is the central resource for transforming groundbreaking ideas and discoveries into new products, services, and ventures at the University of Chicago. A dedicated team of professionals with deep technical expertise exclusively focused on enabling technology commercialization perform market analysis, manage intellectual property, identify partners, and negotiate partnerships and licenses for discoveries and inventions developed by faculty, researchers, and staff.

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website:
www.ab-science.com.

Forward-looking Statements – AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 “Risk Factors” of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science

Financial Communication & Media Relations
[email protected]

Media Relations – USA

RooneyPartners

Jeffrey Freedman
[email protected]

+1 646 432 0191

Media Relations – France

NewCap

Arthur Rouillé
[email protected]

+33 (0)1 44 71 00 15

Attachment

CP Partnership Agreement VEngVF

April 6, 2021 1:48 am

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Credit Suisse Group AG – CS

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Credit Suisse Group AG (“Credit Suisse” or the “Company”) (NYSE: CS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Credit Suisse and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 29, 2021, Credit Suisse disclosed that it anticipated significant losses in connection with positions linked to Archegos Capital Management (“Archegos”) after Archegos failed to meet margin calls the prior week, forcing the liquidation of more than $20 billion in holdings. That same day, Bloomberg reported that “[m]uch of the leverage used by [Archegos] was provided by banks including Nomura Holdings Inc. and Credit Suisse Group AG through swaps and so-called contracts for difference[.]”

On this news, Credit Suisse’s stock price fell $1.48 per share, or 11.5%, to close at $11.39 per share on March 29, 2021.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-credit-suisse-group-ag—cs-301262548.html

SOURCE Pomerantz LLP